Press Room

ASD-HIPROS Learning Lab

Start
Thursday, July 29, 2021 - 00:00
End
Thursday, August 12, 2021 - 00:00
Location: online
Schedule meeting with Hovione ASD-HIPROS Learning Lab | Hovione

Join our exclusive Learning Lab at CPhI North America

ASD-HIPROS - A new platform for quick and effective 
formulation screening for Amorphous Solid Dispersions by Spray Drying”

 

Join our expert. In just 20 minutes you will learn:

  1. Introduction to Hovione’s new formulation screening platform by Spray Drying
  2. Learn about the advantages of a platform that integrates in silico computational models, formulation, analytical development
  3. Get to know more about Hovione’s extensive expertise in Spray Drying

 

REGISTER NOW

 

Synopsis

The number of drug candidates that present low solubility issues has been increasing over the past years. Amorphous Solid Dispersions (ASDs) are an established platform to address bioavailability challenges of poorly soluble drug candidates, offering many of the advantages of more conventional solid oral dosage forms while providing faster dissolution rates and higher drug concentrations. Suboptimal formulations of poorly soluble compounds may result in clinical failures, ultimately increasing the development timeline and associated costs towards identifying a winning candidate. Register now!

 

Targeted at APIs with poor solubility issues, ASD-HIPROS, Hovione’s Intelligent Proprietary Screening, is a methodology able to evaluate if formulations by Spray Drying are viable candidates towards solving poor bioavailability issues. Equipped with a computational platform coupled with state-of-the-art analytical and spray drying technologies, this platform is able to deliver optimal formulations in record time with minimal consumption of API, maximizing the chance of identifying a successful formulation and accelerating development towards clinical supplies.

 

Who should attend:

  1. Formulators
  2. Scientists
  3. Investigators and Research fellows
  4. R&D personnel
  5. Technical services personnel

 

REGISTER NOW

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025